User:Mr. Ibrahem/Apixaban

Apixaban, sold under the brand name Eliquis among others, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation (AF). Specifically it is used to prevent blood clots following hip or knee replacement and in those with a history of prior clots. It is used as an alternative to warfarin and does not require monitoring by blood tests. It is taken by mouth.

Common side effects include bleeding and nausea. Other side effects may include bleeding around the spine and allergic reactions. Use is not recommended during pregnancy or breastfeeding. Use appears to be relatively safe in those with mild kidney problems. Compared to warfarin it has fewer interactions with other medications. It is a direct factor Xa inhibitor.

Apixaban was approved for medical use in the European Union in May 2011 and in the United States in December 2012. It is on the World Health Organization's List of Essential Medicines as an alternative to dabigatran. A month supply in the United Kingdom costs the NHS about £53 as of 2020. In the United States the wholesale cost of this amount is about $427. In 2017, it was the 93rd most commonly prescribed medication in the United States with more than eight million prescriptions. In December 2019, generic versions were approved in the United States.